Blood Reviews

Article	Citations
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	152
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	115
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	111
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	110
Editorial Board	103
Not all LGL leukemias are created equal	87
Radiation and leukaemia: Which leukaemias and what doses?	77
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	65
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	60
Clinical burden of hemophilia in older adults: Beyond bleeding risk	58
Artificial intelligence in sickle disease	54
Thalassaemia in China	52
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	52
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	49
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	46
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	44
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	44
Chasing leukemia differentiation through induction therapy, relapse and transplantation	41
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	38
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	38
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	36
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	36
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	35
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	35

Endothelial cells: major players in acute myeloid leukaemia	34
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	33
Preservation of fertility in female patients with hematologic diseases	32
Immune thrombocytopenia: A review of upfront treatment strategies	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	31
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	31
CHIPing away the progression potential of CHIP: A new reality in the making	30
Coagulation and anticoagulation in COVID-19	30
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	30
Down syndrome and leukemia: An insight into the disease biology and current treatment options	29
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	29
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	28
Current challenges in conditioning regimens for MDS transplantation	28
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	28
The extracellular matrix: A key player in the pathogenesis of hematologic malignancies	27
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia	27
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	27
Richter's transformation: Transforming the clinical landscape	26
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	26
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	25
Management of venous thromboembolism in athletes	25
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	24
Complementary and alternative medicine for children with sickle cell disease: A systematic review	24
Optimizing high dose melphalan	24
The mythological chimera and new era of relapse prediction post-transplant	23
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	23
Αlpha-thalassemia: A practical overview	23
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	21
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	21
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	21
Current state and next-generation CAR-T cells in multiple myeloma	21
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	21
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	20
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	20
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies	19
AML and the art of remission maintenance	19
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	19
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	19
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	19
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	18
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	18
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients	18
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	18
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	18
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	17
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	17
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	17
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	17
Innovations in red blood cell preservation	17
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	16

Discussing investigational AAV gene therapy with hemophilia patients: A guide	16
The use of bone-modifying agents in multiple myeloma	16
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	16
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia	15
Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021	15
Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases	15
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy	15
The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators	15
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	15
Antibiotics to modify sickle cell disease vaso-occlusive crisis?	14
Insight of fetal to adult hemoglobin switch: Genetic modulators and therapeutic targets	14
Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?	14
A review on how to do hematology consults during COVID-19 pandemic	14
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme	13
The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?	13
De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review	13
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	13
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	13
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS	13
Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies	13
Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B	13
Diagnosis and treatment of lymphomas in the era of epigenetics	13
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2	13
Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review	13
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation	13
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol	12
Disparity in hematological malignancies: From patients to health care professionals	12
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	12
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly	12
Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China	12
Chronic myeloid leukaemia: Biology and therapy	12
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies	11
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	11
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review	11
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management	11
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	11
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution	11
Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond	10
Autologous stem cell transplantation in AL amyloidosis: Muddy waters	10
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment	10
Editorial Board	10
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	10
Follicular lymphoma: The long and winding road leading to your cure?	10
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies	10
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches	10
The development of post-transplant cyclophosphamide: Half a century of translational team science	10
Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?	9
BCL-2 inhibition in haematological malignancies: Clinical application and complications	9
Could (should) we abandon total body irradiation for conditioning in children with leukemia	9
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH	9
Continuing progress in radioimmunotherapy for hematologic malignancies	9
Anti-body building: The exercise of advancing immune based myeloma therapies	9
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	9
Decoding DNA methylation in epigenetics of multiple myeloma	9
Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era	9
Dismantling relapsed/refractory mantle cell lymphoma	9
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review	8
Corrigendum to “Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?”[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]	8
A review of FLT3 inhibitors in acute myeloid leukemia	8
Navigating the perils and pitfalls throughout the consent process in hematopoietic cell transplantation	8
From MGUS to multiple myeloma: Unraveling the unknown of precursor states	8
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel	8
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	8
Acupuncture in hematologic malignancies and hematopoietic cell transplantation	8
Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis	8
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances	8
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	8
Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma	8
CLL update 2022: A continuing evolution in care	8
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies	7
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	7
Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial	7
Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management	7
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	7
Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization	7
Aiming for the cure in myeloma: Putting our best foot forward	7
Knowing the unknowns in high risk multiple myeloma	7
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	7
Editorial Board	7
Advances in the management of TTP	7

Editorial Board

7